A pilot study of the safety and efficacy of cholestin in treating HIV-related dyslipidemia.

Abstract

OBJECTIVE:

We collected preliminary safety and efficacy data on the effects of Cholestin, a statin-containing dietary supplement, in individuals with dsylipidemia related to human immunodeficiency virus.

METHODS:

Fourteen adults with dsylipidemia related to human immunodeficiency virus characterized by hypercholesterolemia, hypertriacylglycerolemia, or both participated in a randomized, double-blind, placebo-controlled pilot study in an infectious disease clinic based in an academic medical center. Participants were randomly assigned to receive 1.2 g of Cholestin twice daily (n = 7) or placebo (n = 7) for 8 wk. The main outcome measures were safety (hepatic function tests, plasma human immunodeficiency virus-1 RNA levels, CD4(+) cell counts, adverse effects) and efficacy (fasting serum cholesterol: total, high- and low-density lipoproteins, and fasting serum triacylglycerols). Safety and efficacy outcomes were evaluated at 2- and 8-wk intervals.

RESULTS:

Twelve participants (n = 6 per group) completed the 8-wk treatment protocol. After 8 wk of treatment with Cholestin, there were significant declines from baseline in mean (+/- standard error of the mean) fasting total cholesterol (-30.8 +/- 8.8 versus 7.7 +/- 5.6; P = 0.01) and low-density lipoprotein cholesterol (-32.2 +/- 7.2 versus 26.3 +/- 14.2; P = 0.01) versus placebo. Moreover, the decline in fasting total cholesterol was significant (-40.2 +/- 4.8 versus 2.8 +/- 11.9; P = 0.006) after 2 wk of therapy, at which time the low-density lipoprotein cholesterol approached significance (-30.2 +/- 7.4 versus 4.4 +/- 15.2; P = 0.068). High-density lipoprotein cholesterol and triacylglycerol levels did not change at either time point. No adverse effects were seen with Cholestin.

CONCLUSIONS:

Cholestin may safely lower total and low-density lipoprotein cholesterol in patients with dsylipidemia related to human immunodeficiency virus. Larger and longer-term trials of this approach are warranted.

• Authors: Joyce K Keithley, Barbara Swanson, Beverly E Sha, Janice M Zeller, Harold A Kessler, Kimberly Y Smith
• Journal: Nutrition (Burbank, Los Angeles County, Calif.) (Nutrition) Vol. 18 Issue 2 Pg. 201-4 (Feb 2002) ISSN: 0899-9007 [Print] United States
• PMID: 11844656 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Anticholesteremic Agents
• Biological Products
• Cholesterol, HDL
• Cholesterol, LDL
• Triglycerides
• red yeast rice
• Cholesterol

Topics

• Adult
• Anticholesteremic Agents (pharmacology, therapeutic use)
• Biological Products (pharmacology, therapeutic use)
• Cholesterol (blood)
• Cholesterol, HDL (blood)
• Cholesterol, LDL (blood)
• Double-Blind Method
• Female
• HIV Infections (complications, physiopathology)
• Humans
• Hyperlipidemias (drug therapy, etiology)
• Liver Function Tests
• Male
• Pilot Projects
• Safety
• Treatment Outcome
• Triglycerides (blood)
• Viral Load